Neurological paraneoplastic syndromes.
Paraneoplastic neurological syndromes are uncommon, however, their diagnosis is of major practical importance. The identification of antibodies in the serum or cerebrospinal fluid in central nervous system paraneoplastic syndromes confirms the clinical diagnosis of a paraneoplastic syndrome and allows early identification of an underlying tumour at a stage when it is localised and more amenable to treatment. The failure to identify antibodies in patients with characteristic presentations of underlying neurological paraneoplastic syndromes does not exclude an underlying cancer. Necrotising myelopathy, dermatomyositis, and chronic inflammatory demyelinating polyneuropathy all occur more frequently than expected in patients with cancer but autoantibodies have not yet been identified. Although significant advances have been made in diagnosis, further research is needed in the detection of autoantibodies and the elucidation of their role in the aetiology of neurological disease.
Nath
U
U
Department of Clinical Neurosciences, Western General Hospital, Edinburgh, UK.
Grant
R
R
D001323:Autoantibodies / Q000032:analysis; D002526:Cerebellar Diseases / Q000276:immunology; D004679:Encephalomyelitis / Q000276:immunology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D015624:Lambert-Eaton Myasthenic Syndrome / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009422:Nervous System Diseases / Q000145:classification / Q000276:immunology*; D015835:Ocular Motility Disorders / Q000276:immunology; D010257:Paraneoplastic Syndromes / Q000145:classification / Q000276:immunology*; D011689:Purkinje Cells / Q000276:immunology; D012164:Retinal Diseases / Q000276:immunology
D001323:Autoantibodies